Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 464 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 The vaccination of a generation? – That Cancer Conversation December 9, 2021 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Load more HOT NEWS Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... Darolutamide Delays the Spread of Some Prostate Cancers Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting...
